About clinical guidelines

Disclosure of interests 

Early detection of cancer in AYAs

Psychosocial management of AYAs diagnosed with cancer

Adolescents and young adults (AYA)

Colorectal cancer

Surveillance colonoscopy

Bowel cancer

Cancer pain management

Cancer therapy medication safety

Cervical cancer screening

Cervical cancer 

Endometrial cancer

Summary of recommendations

Impact on fertility

Discussing Risk

Referral and service provision

Psychological support 

Options for treatment

Pubertal development

Contraception 

Conception

Pregnancy

Appendices

Fertility preservation for people with cancer

Head and neck cancer

Liver cancer

Lung cancer prevention and diagnosis 

Lung cancer treatment

Lung cancer

Management of communication and swallowing

Neuroendocrine neoplasms (NENs)

Barrett’s oesophagus

Oesophageal cancer

PSA testing

Prostate cancer

Melanoma

Keratinocyte cancer

Skin cancer

Teleoncology

Browse all guidelines

Archived guidelines

Foreword

Introduction

1. Cervical cancer in Australia

2. The rationale for primary HPV screening

HPV testing terminology

Cytology and AMBS 2004 terminology for reporting 

Preparation of cervical screening reports

Histopathology

Supplement: Sample reports

3. Terminology

4. Unsatisfactory cervical screening results

5. Benefits, harms and cost-effectiveness in renewed National Cervical Screening Program (NCSP)

Medical Services Advisory Committee recommendations for HPV testing

Oncogenic HPV types not detected

Oncogenic HPV types 16 and/or 18

Oncogenic HPV types not 16/18

Self-collected vaginal samples

Women undergoing exit testing

Screening in women older than 75

Discussion

Flowcharts

6. Management of oncogenic HPV test results

Colposcopy terminology

Principles of practice

History, examination and investigation

Colposcopy and treatment

Colposcopy data for the National Cancer Screening Register

Quality improvement in colposcopy

Supplement. Colposcopy information for discussion with patient

Supplement. Colposcopy technologies and documentation

7. Colposcopy

Normal colposcopic findings following LBC prediction of Negative, LSIL or HSIL

Type 3 TZ (previously termed ‘unsatisfactory’) colposcopy following LBC prediction of Negative, LSIL or HSIL

Discussion: Management of discordant colposcopic impression, histopathology and referral LBC prediction

8. Management of discordant colposcopic impression, histopathology and referral LBC prediction

9. Management of histologically confirmed low-grade squamous abnormalities

Diagnosis of high-grade squamous abnormalities 

Treatment of high-grade squamous abnormalities 

Test of Cure after treatment for HSIL (CIN2/3)

Discussion: Management of histologically confirmed high-grade squamous abnormalities

10. Management of histologically confirmed high-grade squamous abnormalities

Investigation of cytological glandular abnormalities

Follow-up after excisional treatment for AIS

Discussion: Management of histologically confirmed high-grade glandular abnormalities

11. Management of glandular abnormalities

12. HPV screening strategies for Aboriginal and Torres Strait Islander women

13. Screening after total hysterectomy

14. Screening in pregnancy

15. Women experienced early sexual activity or victims of abuse 

16. Screening in immune-deficient women

17. DES-exposed women

Investigation of abnormal vaginal bleeding

Investigations of other symptoms: vaginal discharge and deep dyspareunia

18. Signs and symptoms of cervical cancer

19. Psychosocial care

20. Transition to the renewed National Cervical Screening Program

A. Modelled evaluation of the predicted benefits, harms and cost-effectiveness of the renewed National Cervical Screening Program (NCSP)

B. Guideline development process

C. Clinical question list

D. Technical report

E. Working party members and contributors and project team contributions

F. Project team contributions

G. Conflict of interest register

H. Safety monitoring of the Renewed cervical screening program

I. Glossary of terms and abbreviations

J. Safety monitoring of renewed cervical screening program

Pregnancy and live birth

Ovarian function

Testicular function

Reproductive concerns

Health professional awareness

Role of oncology services

Referral rates

Referral pathways

Service provision

Fertility counselling

Decision making

Sperm cryopreservation

Testicular biopsy

Embryo cryopreservation

Oocyte cryopreservation

Ovarian stimulation

Ovarian tissue cryopreservation

Ovarian transposition

Ovarian suppression

During treatment

After treatment

Interrupting therapy

Assisted reproduction

Pregnancy of recurrence

Risk of complications

Guideline development process

Working Group

Additional resources

<p><a href="https://wiki.cancer.org.au/australia/Code_of_Practice_Competing_Interest" title="Code of Practice Competing Interest"><strong>A Code of Practice for Declaring and Dealing with Competing Interests</strong></a><br>
</p>
<kentico-component type="application/kenticocloud" data-type="item" data-rel="component" data-codename="n6688ac6e_014c_01d2_7b36_22bfe5bc3934" data-sdk-resolved="1" class="custom-rich-text"><div data-kontent-item-id="6688ac6e-014c-01d2-7b36-22bfe5bc3934" data-kontent-element-codename="title"><a href="/assets/pdf/Cerv_Competing_Interest_register.pdf" target="_blank" rel="noopener noreferrer" class="resource_tile"><div class="grid grid__gutter--5 grid__verticalSpacing--1  resource_tile__inner"><div class="row  row__gutter--6  "><div class="column column--xs--1 column--sm--2  "><div class="resource_tile__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 239.5 320" width="1em" height="1em"><path fill="currentColor" d="M68.75 162.21a3.86 3.86 0 003.86 3.86H183.2a3.86 3.86 0 100-7.71H72.61a3.85 3.85 0 00-3.86 3.85zM183.2 186H58.75a3.86 3.86 0 100 7.71H183.2a3.86 3.86 0 100-7.71zM141.75 213.65h-83a3.86 3.86 0 100 7.72h83a3.86 3.86 0 000-7.72zM58.51 166a3.83 3.83 0 10-3.55-4.1 3.83 3.83 0 003.55 4.1zM76.85 82c-3.44 0-6.1-2.2-6.1-5.62V37.57a6 6 0 1112 0V70h78V38.47c0-.46.05-11.55-6.7-18.39-3.69-3.75-8.91-5.65-15.63-5.65a127.38 127.38 0 00-22.81 2.22 114.07 114.07 0 01-20 2c-7.88 0-14-1.24-19.39-3.89l-.13-.07a8.68 8.68 0 01-4.73-8c0-3.61.61-5.32 2.26-6.1l1.41-.67 1.26.93a35.61 35.61 0 003.63 2.33h.09c.52.3 5.45 2.95 15.61 2.95a104.59 104.59 0 0018-1.87A137.75 137.75 0 01138.45 2c10.08 0 18.17 3.16 24.29 9.41 9.4 9.58 10 23.18 10 27.12v37.86a5.25 5.25 0 01-5.64 5.62z"></path><path fill="currentColor" d="M211.5 320H0V65.5a28 28 0 0128-28h30.75v16H28a12 12 0 00-12 12V304h195.5a12 12 0 0012-12V53.5H182v-16h57.5V292a28 28 0 01-28 28z"></path></svg></div></div><div class="column column--xs--10 column--sm--9  "><div class="resource_tile__title">Declarations of interest register (partial update 2020)</div><div class="resource_tile__text">Declarations of interest register (partial update 2020)</div></div><div class="column column--xs--2 column--sm--1  "><div class="resource_tile__action"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 281.22 270.41" width="1em" height="1em"><path fill="currentColor" d="M205.67 223.78zM205.69 231.78a8 8 0 010-16 8 8 0 010 16zM230.23 223.78zM230.25 231.78a8 8 0 010-16 8 8 0 010 16zM217.48 110.02a8.19 8.19 0 00-6.39-2.89h-20.65a29 29 0 00-21.4 9.45l-5.88 6.45a9.41 9.41 0 001.2.09h30.53l-54 68.93-54-68.93h30.52a8 8 0 008-8V16h30.95v69.23a15.94 15.94 0 0016 15.94V8a8 8 0 00-8-8h-46.95a8 8 0 00-8 8v99.13H70.69a8.22 8.22 0 00-6.39 2.88 8 8 0 00-.14 10.05l70.45 89.9a8 8 0 006.3 3.06 8 8 0 006.3-3.06l70.4-89.9a8 8 0 00-.14-10z"></path><path fill="currentColor" d="M252.73 176.16h-41.84a16 16 0 00-16 16h57.84a12.49 12.49 0 0112.49 12.48v37.28a12.49 12.49 0 01-12.49 12.49H28.49A12.49 12.49 0 0116 241.92v-37.28a12.49 12.49 0 0112.49-12.48H86.1a16 16 0 00-16-16H28.49A28.49 28.49 0 000 204.64v37.28a28.49 28.49 0 0028.49 28.49h224.24a28.49 28.49 0 0028.49-28.49v-37.28a28.49 28.49 0 00-28.49-28.48z"></path></svg></div></div></div></div></a></div></kentico-component>
<p><a data-item-id="52a705a0-c091-4871-afdf-b5e2b592b626" href="/clinical-guidelines/cervical-cancer/cervical-cancer-screening/appendices/declarations-of-interest-register">Declarations of interest register (partial update 2020)</a> (see:&nbsp;<a data-item-id="52a705a0-c091-4871-afdf-b5e2b592b626" href="/clinical-guidelines/cervical-cancer/cervical-cancer-screening/appendices/declarations-of-interest-register">Guideline development process – 2020 partial update</a>)</p>
<kentico-component type="application/kenticocloud" data-type="item" data-rel="component" data-codename="n86685daa_b055_014a_2741_46635095332b" data-sdk-resolved="1" class="custom-rich-text"><div data-kontent-item-id="86685daa-b055-014a-2741-46635095332b" data-kontent-element-codename="title"><a href="/assets/pdf/conflict-of-interest-register-cervical-management-guidelines.pdf" target="_blank" rel="noopener noreferrer" class="resource_tile"><div class="grid grid__gutter--5 grid__verticalSpacing--1  resource_tile__inner"><div class="row  row__gutter--6  "><div class="column column--xs--1 column--sm--2  "><div class="resource_tile__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 239.5 320" width="1em" height="1em"><path fill="currentColor" d="M68.75 162.21a3.86 3.86 0 003.86 3.86H183.2a3.86 3.86 0 100-7.71H72.61a3.85 3.85 0 00-3.86 3.85zM183.2 186H58.75a3.86 3.86 0 100 7.71H183.2a3.86 3.86 0 100-7.71zM141.75 213.65h-83a3.86 3.86 0 100 7.72h83a3.86 3.86 0 000-7.72zM58.51 166a3.83 3.83 0 10-3.55-4.1 3.83 3.83 0 003.55 4.1zM76.85 82c-3.44 0-6.1-2.2-6.1-5.62V37.57a6 6 0 1112 0V70h78V38.47c0-.46.05-11.55-6.7-18.39-3.69-3.75-8.91-5.65-15.63-5.65a127.38 127.38 0 00-22.81 2.22 114.07 114.07 0 01-20 2c-7.88 0-14-1.24-19.39-3.89l-.13-.07a8.68 8.68 0 01-4.73-8c0-3.61.61-5.32 2.26-6.1l1.41-.67 1.26.93a35.61 35.61 0 003.63 2.33h.09c.52.3 5.45 2.95 15.61 2.95a104.59 104.59 0 0018-1.87A137.75 137.75 0 01138.45 2c10.08 0 18.17 3.16 24.29 9.41 9.4 9.58 10 23.18 10 27.12v37.86a5.25 5.25 0 01-5.64 5.62z"></path><path fill="currentColor" d="M211.5 320H0V65.5a28 28 0 0128-28h30.75v16H28a12 12 0 00-12 12V304h195.5a12 12 0 0012-12V53.5H182v-16h57.5V292a28 28 0 01-28 28z"></path></svg></div></div><div class="column column--xs--10 column--sm--9  "><div class="resource_tile__title">Declarations of interest register (2016)</div><div class="resource_tile__text">Declarations of interest register (2016)</div></div><div class="column column--xs--2 column--sm--1  "><div class="resource_tile__action"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 281.22 270.41" width="1em" height="1em"><path fill="currentColor" d="M205.67 223.78zM205.69 231.78a8 8 0 010-16 8 8 0 010 16zM230.23 223.78zM230.25 231.78a8 8 0 010-16 8 8 0 010 16zM217.48 110.02a8.19 8.19 0 00-6.39-2.89h-20.65a29 29 0 00-21.4 9.45l-5.88 6.45a9.41 9.41 0 001.2.09h30.53l-54 68.93-54-68.93h30.52a8 8 0 008-8V16h30.95v69.23a15.94 15.94 0 0016 15.94V8a8 8 0 00-8-8h-46.95a8 8 0 00-8 8v99.13H70.69a8.22 8.22 0 00-6.39 2.88 8 8 0 00-.14 10.05l70.45 89.9a8 8 0 006.3 3.06 8 8 0 006.3-3.06l70.4-89.9a8 8 0 00-.14-10z"></path><path fill="currentColor" d="M252.73 176.16h-41.84a16 16 0 00-16 16h57.84a12.49 12.49 0 0112.49 12.48v37.28a12.49 12.49 0 01-12.49 12.49H28.49A12.49 12.49 0 0116 241.92v-37.28a12.49 12.49 0 0112.49-12.48H86.1a16 16 0 00-16-16H28.49A28.49 28.49 0 000 204.64v37.28a28.49 28.49 0 0028.49 28.49h224.24a28.49 28.49 0 0028.49-28.49v-37.28a28.49 28.49 0 00-28.49-28.48z"></path></svg></div></div></div></div></a></div></kentico-component>
<p><a data-item-id="52a705a0-c091-4871-afdf-b5e2b592b626" href="/clinical-guidelines/cervical-cancer/cervical-cancer-screening/appendices/declarations-of-interest-register">Declarations of interest register (2016)</a>&nbsp;<br>
&nbsp;</p>

Clinical Guidelines

G. Conflict of interest register

Appendix G